Phenotypes Associated with This Genotype

Genotype
MGI:6378723

• Allelic Composition: Rasa3^scat/Rasa3^scat
• Genetic Background: involves: BALB/cBy * BALB/cByJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal cell cycle checkpoint function ( J:281271 )

• diminished progression out of G0/G1 into S or G2 at the basophilic and polychromatophilic stages of erythroid development

decreased apoptosis ( J:281271 )

• decreased apoptosis is found in the proerythroblastic, polychromatic, and orthochromatic stages of erythroid development in both spleen and bone marrow

oxidative stress ( J:281271 )

• increased ROS at the proerythroblastic stage assessed in splenocytes, and a trend for increased ROS levels throughout erythroid differentiation and in peripheral reticulocytes

growth/size/body

increased spleen weight ( J:301035 )

• as a percentage of body weight the splenic weight in homozygotes between 3-5 weeks of age is more than 4 times that of controls

immune system

increased spleen weight ( J:301035 )

• as a percentage of body weight the splenic weight in homozygotes between 3-5 weeks of age is more than 4 times that of controls

decreased leukocyte cell number ( J:301035 )

• between 3 to 5 weeks of age, 2800 (+/- 1800)/uL in homozygotes versus 4900 (+/-1200)/uL in controls

hematopoietic system

increased spleen weight ( J:301035 )

• as a percentage of body weight the splenic weight in homozygotes between 3-5 weeks of age is more than 4 times that of controls

abnormal erythropoiesis ( J:281271 )

abnormal erythroblast morphology ( J:281271 )

decreased erythrocyte cell number ( J:301035 )

• between 3 to 5 weeks of age, 3.8 (+/-1.1) x 10⁶ in homozygotes versus 8.8 (+/-0.7) x 10⁶ in controls

decreased hematocrit ( J:301035 )

• between 3 to 5 weeks of age, 22.2 (+/-6.9)% in homozygotes versus 41.6 (+/-3.2)% in controls

increased hemoglobin concentration distribution width ( J:301035 )

• between 3 to 5 weeks of age, 3.3 (+/- .04) g/dL in homozygotes versus 2.3 (+/- 0.2) g/dL in controls

decreased hemoglobin content ( J:301035 )

• between 3 to 5 weeks of age, 5.8 (+/-1.9) g/dL in homozygotes versus 13.9 (+/-1.2) g/dL in controls

decreased mean corpuscular hemoglobin concentration ( J:301035 )

• between 3 to 5 weeks of age, 25.7 (+/-4.2) g/dL in homozygotes versus 33.5 (+/-1.5) g/dL in controls

increased mean corpuscular volume ( J:301035 )

• between 3 to 5 weeks of age, 57.8 (+/-4.3)fL in homozygotes versus 47.4 (+/-1.3)% in controls

increased red blood cell distribution width ( J:301035 )

• between 3 to 5 weeks of age, 28.0 (+/- 6) % in homozygotes versus 19.7 (+/-2.2) % in controls

thrombocytopenia ( J:301035 )

• between 3 to 5 weeks of age 103000 (+/- 106000) platelets per uL in homozygotes versus 595000 (+/- 281000) per uL in controls

increased mean platelet volume ( J:301035 )

• between 3 to 5 weeks of age, 8.9 (+/-1.3) fL in homozygotes versus 5.2 (+/-.03) fL in controls

decreased leukocyte cell number ( J:301035 )

• between 3 to 5 weeks of age, 2800 (+/- 1800)/uL in homozygotes versus 4900 (+/-1200)/uL in controls

reticulocytosis ( J:301035 )

• between 3 to 5 weeks of age, 45.1 (+/-12) % in homozygotes versus 9.5 (+/- 3.6) % in controls

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
aplastic anemia		DOID:12449	OMIM:609135	J:281271